David Kuter, M.D., DPHIL

Physician Investigator (Cl)
Cancer Center, Mass General Research Institute
Professor of Medicine
Harvard Medical School
Medicine-Hematology/Oncology, Massachusetts General Hospital
D.Phil. Oxford University 1974
MD Harvard Medical School 1978
anti-cd40 ligand antibody; blood platelets; hemin; heparin-induced thrombocytopepenia; hereditary hemorrhagic telangiectasis; idiopathic; immune thrombocytopenia; platelet function; polycythemia vera; purpura thrombocytopenic; receptors fc; receptors thrombopoietin; romiplostim; thrombocytopenia; thrombopoietin; tpo receptor agonists; transfusion medicine Dr. David Kuter is Director of Clinical Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. He received his undergraduate degree from Harvard College and his D. Phil. in Biochemistry while a Rhodes Scholar at Oxford University, before obtaining his medical degree from Harvard Medical School.

Dr. Kuter divides his time between medical education of fellows and medical students, clinical care of patients with a wide range of hematological disorders, and clinical research of thrombopoietic agents.

His basic science group was one of the labs that discovered thrombopoietin and his clinical research group carried out seminal studies using thrombopoietic agents in transfusion medicine and immune thrombocytopenia (ITP).

Current areas of ongoing research:
  1. Hereditary hemorrhagic telangiectasis (HHT): NIH sponsored grant to assess effect of pamolidomide to reduce bleeding in patients with HHT.
  2. Immune thrombocytopenia (ITP): NIH sponsored grant to assess effect of addition of mycophenolyate to standard of care for patients with ITP.
  3. Heparin-induced thrombocytopepenia (HIT): lead in 17 center NIH-sponsored study of the natural history and treatment of HIT
  4. Polycythemia vera (P.vera): Incyte Corp study (Reveal Study) to assess the natural history, treatment and quality of life of patients with P. vera.
  5. ITP: Ph 1 study using anti-CD40 ligand antibody (BMS sponsor) to reduce the rate of thrombocytopenia in patients with ITP
  6. ITP: Ph 1 study assessing the use of Staph protein A (Protalix, Inc) in the treatment of ITP
  7. ITP: assessment of patients with ITP treated with TPO receptor agonists--effect on longterm remission
  8. ITP: assessment of TPO receptor agonists in raising the platelet count of thrombocytopenic patients about to have surgery
  9. ITP: study of platelet function in patients with ITP after treatment with romiplostim
  10. Autoimmune hemolytic anemia (AIHA): creator and major site for international registry for patients with this disorder.

Dr Kuter is recipient of a number of awards, including the Irving London Teaching Award at Harvard Medical School, the Alfred Kranes Teaching Award at the Massachusetts General Hospital, the Douglas Family Foundation Prize for Research (2008 and 2010) at Massachusetts General Hospital, the Jane Green Memorial Prize for Teaching at the Massachusetts General Hospital, and the 2013 Earnest Beutler Award from the American Society of Hematology.

He has given over 500 invited lectures in over 50 countries and served as Visiting Professor in Beijing, Sydney, Tokyo, London, Durham, and New Haven.

Dr Kuter has authored or co-authored over 300 articles published in international peer-reviewed journals such as The Lancet, The New England Journal of Medicine and Blood.

Publications Clinical Profile

Yawkey Center Outpatient Care
32 Fruit Street
Boston, MA 02114